Positive News SentimentPositive NewsNASDAQ:EQ Equillium (EQ) Stock Price, News & Analysis $1.82 -0.09 (-4.71%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$1.82 -0.01 (-0.27%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Equillium Stock (NASDAQ:EQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Equillium alerts:Sign Up Key Stats Today's Range$1.73▼$1.9650-Day Range$0.29▼$1.9552-Week Range$0.27▼$2.26Volume1.41 million shsAverage Volume23.43 million shsMarket Capitalization$108.30 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingHold Company Overview Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Read More Equillium Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreEQ MarketRank™: Equillium scored higher than 27% of companies evaluated by MarketBeat, and ranked 875th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingEquillium has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageEquillium has received no research coverage in the past 90 days.Read more about Equillium's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Equillium are expected to decrease in the coming year, from $0.14 to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 22.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Equillium's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.43% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently decreased by 53.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.43% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently decreased by 53.10%, indicating that investor sentiment is improving significantly. News and Social Media4.4 / 5News Sentiment1.83 News SentimentEquillium has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Equillium this week, compared to 1 article on an average week.Search Interest15 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows4 people have added Equillium to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have not sold or bought any company stock.Percentage Held by Insiders31.60% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.05% of the stock of Equillium is held by institutions.Read more about Equillium's insider trading history. Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EQ Stock News HeadlinesEquillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UCAugust 28 at 6:06 PM | seekingalpha.comEquillium price target lowered to $4 from $8 at JefferiesAugust 20, 2025 | msn.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the ClinicAugust 11, 2025 | finance.yahoo.comEquillium Secures $30 Million in Private PlacementAugust 11, 2025 | tipranks.comEquillium Shares Drop 12.4% After Unveiling Cryptocurrency Treasury StrategyAugust 4, 2025 | msn.comSpotlight On 3 Promising Penny Stocks With Over $20M Market CapAugust 4, 2025 | finance.yahoo.comEquillium stock falls after announcing cryptocurrency treasury strategyAugust 4, 2025 | au.investing.comSee More Headlines EQ Stock Analysis - Frequently Asked Questions How have EQ shares performed this year? Equillium's stock was trading at $0.7482 at the start of the year. Since then, EQ stock has increased by 143.3% and is now trading at $1.82. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02. Equillium had a negative trailing twelve-month return on equity of 139.56% and a negative net margin of 19.62%. When did Equillium IPO? Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Equillium own? Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray Brands (TLRY) and Carnival (CCL). Company Calendar Last Earnings8/14/2025Today8/28/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EQ CIK1746466 Webequilliumbio.com Phone(858) 240-1200FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Equillium$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside-45.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E Ratio13.00 P/E GrowthN/ANet Income-$8.07 million Net Margins-19.62% Pretax Margin-119.82% Return on Equity-139.56% Return on Assets-90.56% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$41.10 million Price / Sales2.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book22.75Miscellaneous Outstanding Shares59,500,000Free Float40,700,000Market Cap$108.29 million OptionableNot Optionable Beta1.15 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:EQ) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.